rabeprazole has been researched along with Myelodysplastic Syndromes in 1 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasu, T | 1 |
| Konuma, T | 1 |
| Kato, S | 1 |
| Kurokawa, Y | 1 |
| Takahashi, S | 1 |
| Tojo, A | 1 |
1 other study available for rabeprazole and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Body Weight; Bone Marrow Transplan | 2016 |